-
2023-11-14
优锐医药助力2023中国医疗健康峰会
优锐受邀参加第十届 BioCentury-BayHelix 中国医疗健康峰会
-
2023-06-28
Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
Nuance Pharma announces its partner, Verona Pharma plc (Nasdaq: VRNA), has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of ensifentrine fo
-
2023-06-27
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
Verona Pharma plc (Nasdaq: VRNA) announces the submission of a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for approval of ensifentrine for the maintenance treatment of patients with chron
-
2023-05-26
Nuance Pharma's Partner Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
Altamira Therapeutics Ltd. (Nasdaq: CYTO) announced positive and statistically significant top-line results from the randomized controlled NASAR clinical trial evaluating its Bentrio nasal spray in patients with seas
-
2023-05-24
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis
-
2023-04-25
优锐医药First-in-Class慢阻肺管线中国III期顺利启动，加速推进呼吸特药精耕
动脉网获悉，专注呼吸类创新药的生物医药公司：优锐医药，已经于2023年4月6日完成Ensifentrine ENHANCE - CHINAIII期临床试验的首例患者给药，适用于中国大陆区域慢性阻塞性肺疾病(COPD)疾病的维持治疗。
-
2023-04-24
优锐医药受邀出席中关村肾病血液净化创新联盟 “峥嵘五年 再续华章” 五周年庆典
优锐医药荣获联盟颁发的【企业公益大使形象TOP10】奖项
-
2023-04-10
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE - China Phase 3 trial for the maintenance treatment of chronic obstr
Contact PR
